1. Home
  2. HOWL vs NRSN Comparison

HOWL vs NRSN Comparison

Compare HOWL & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Werewolf Therapeutics Inc.

HOWL

Werewolf Therapeutics Inc.

HOLD

Current Price

$0.55

Market Cap

30.7M

Sector

Health Care

ML Signal

HOLD

Logo NeuroSense Therapeutics Ltd.

NRSN

NeuroSense Therapeutics Ltd.

HOLD

Current Price

$0.86

Market Cap

26.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HOWL
NRSN
Founded
2017
2017
Country
United States
Israel
Employees
N/A
16
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
30.7M
26.5M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
HOWL
NRSN
Price
$0.55
$0.86
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
2
Target Price
$5.00
$8.50
AVG Volume (30 Days)
452.4K
144.2K
Earning Date
05-05-2026
03-31-2026
Dividend Yield
N/A
N/A
EPS Growth
18.40
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$583.67
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.50
$0.63
52 Week High
$2.23
$2.60

Technical Indicators

Market Signals
Indicator
HOWL
NRSN
Relative Strength Index (RSI) 32.14 56.30
Support Level N/A $0.85
Resistance Level $0.74 $0.86
Average True Range (ATR) 0.08 0.06
MACD -0.02 0.00
Stochastic Oscillator 13.45 46.53

Price Performance

Historical Comparison
HOWL
NRSN

About HOWL Werewolf Therapeutics Inc.

Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.

About NRSN NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.

Share on Social Networks: